GOSS — Gossamer Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728117 ·
Last close
$0.17
Market Cap
$85.55M
52W High
$0.27
52W Low
$0.11
ADV30
39,426,383
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 16,955,000 | — | -44,866,000 | -46,664,000 | 128,899,000 | 41,028,000 | 290,382,000 |
| Dec 2025 | 13,799,000 | — | -46,040,000 | -47,238,000 | 172,249,000 | 37,732,000 | 295,009,000 |
| Sep 2025 | 13,294,000 | — | -41,638,000 | -48,221,000 | 208,820,000 | 8,933,000 | 291,153,000 |
| Jun 2025 | 11,489,000 | — | -38,765,000 | -38,273,000 | 240,925,000 | 26,309,000 | 287,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-170,263,000
Investing CF
$175,902,000
Financing CF
$6,433,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,485,602,000
Inventory
—
Receivables
$9,252,000
ST Investments
$58,187,000
EBIT TTM
$-169,486,000
Pretax Income TTM
$-180,484,000
Interest Exp TTM
$10,998,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$53,286,000
EBITDA
$-158,596,992
Free Cash Flow
$-29,764,624
Enterprise Value
$58,666,588
Total Cash
$57,026,000
Total Debt
$40,068,000
Shares Out
488,846,722
Trailing EPS
$-0.66
Book Value
$-0.19
ROE
—
ROA
-62.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,471,000 | -163,253,000 | -170,370,000 | 172,249,000 | 295,009,000 | — | -171,266,000 |
| Dec 2024 | 114,701,000 | -59,919,000 | -56,528,000 | 315,292,000 | 285,800,000 | — | -3,468,000 |
| Dec 2023 | 0 | -173,759,000 | -179,817,000 | 311,916,000 | 249,147,000 | — | -159,158,000 |
| Dec 2022 | 0 | -218,528,000 | -229,378,000 | 272,450,000 | 260,373,000 | — | -187,032,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$10,136,000
NetIncome TTM
$-190,421,000
OpCashFlow TTM
$0
Assets (Latest)
$315,292,000
Forward EPS
$-0.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFVN | Lifevantage Corp | $86.29M | $6.84 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| DWTX | Dogwood Therapeutics, Inc. | $87.02M | $2.56 | — |
| GANX | Gain Therapeutics, Inc. | $87.29M | $2.00 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $83.66M | $4.87 | — |
News headlines (Yahoo Finance, 1h cache)
Gossamer Bio announces $250m in funding to advance seralutinib
2026-08-24 10:15 · Yahoo
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval
2026-08-21 13:49 · Yahoo
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell
2026-08-21 12:34 · Yahoo
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
2026-08-21 12:00 · Yahoo
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib
2026-08-17 03:17 · Yahoo
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:01 · Yahoo
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update
2026-08-01 02:06 · Yahoo
Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment
2026-07-28 08:19 · Yahoo
Gossamer Bio shares jump after FDA update and seralutinib rights return
2026-07-27 13:33 · Yahoo
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes
2026-07-02 14:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.